Published in J Biol Chem on March 11, 2009
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res (2010) 1.22
Chemistry of the cysteine sensors in Kelch-like ECH-associated protein 1. Antioxid Redox Signal (2010) 1.05
Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. J Biochem Mol Toxicol (2012) 1.04
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov (2015) 1.01
Immunotoxicity and biodistribution analysis of arsenic trioxide in C57Bl/6 mice following a 2-week inhalation exposure. Toxicol Appl Pharmacol (2009) 0.94
Activation of the Nrf2 pathway by inorganic arsenic in human hepatocytes and the role of transcriptional repressor Bach1. Oxid Med Cell Longev (2013) 0.91
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia (2012) 0.91
TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System. Antioxid Redox Signal (2015) 0.90
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res (2012) 0.86
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br J Cancer (2014) 0.82
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. PLoS One (2012) 0.78
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol (2017) 0.75
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun (1997) 14.09
Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol (2007) 12.48
Bilirubin is an antioxidant of possible physiological importance. Science (1987) 11.26
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A (2001) 6.78
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A (2002) 4.38
Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal (2005) 4.20
Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem (2002) 4.14
Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 4.04
Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol (2006) 3.97
Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem (2002) 3.81
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med (2000) 3.41
The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med (2004) 2.22
Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem (2003) 2.06
Nrf2 as a novel molecular target for chemoprevention. Cancer Lett (2004) 1.95
How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol (2006) 1.94
Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol (2001) 1.89
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood (1999) 1.83
Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol (2006) 1.80
Arsenical-based cancer drugs. Cancer Treat Rev (2007) 1.78
PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. J Biol Chem (2006) 1.78
Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proc Natl Acad Sci U S A (2004) 1.64
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia (2004) 1.63
Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. Mol Cell Biol (2006) 1.45
Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol (2007) 1.44
Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid Redox Signal (2002) 1.40
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood (2001) 1.36
Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res (2000) 1.34
Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun (2005) 1.32
Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl Acad Sci U S A (2005) 1.32
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood (2008) 1.27
Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene (2004) 1.26
Inducers of heme oxygenase-1. Curr Pharm Des (2008) 1.24
Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene (2006) 1.24
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene (2005) 1.15
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res (2002) 1.15
Heme oxygenase -1 gene therapy: recent advances and therapeutic applications. Curr Gene Ther (2007) 1.14
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther (2002) 1.11
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem (2006) 1.11
Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis (2004) 1.10
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem (2006) 1.10
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma (2006) 1.04
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther (2003) 1.02
Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia (2002) 1.01
Arsenic binding to human metallothionein. J Am Chem Soc (2006) 1.01
Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res (2006) 0.97
Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol (2005) 0.95
The role of GSH efflux in staurosporine-induced apoptosis in colonic epithelial cells. Biochem Pharmacol (2008) 0.94
Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci (2006) 0.92
Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer (2004) 0.92
Differential roles for Nrf2 and AP-1 in upregulation of HO-1 expression by arsenite in murine embryonic fibroblasts. Free Radic Res (2008) 0.91
Arsenic induces and enhances rat hepatic metallothionein production in vivo. Chem Biol Interact (1992) 0.91
ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. Biochem Biophys Res Commun (2007) 0.88
Staurosporin induces neurite outgrowth through ROS generation in HN33 hippocampal cell lines. J Neural Transm (Vienna) (2006) 0.88
Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer (2002) 0.85
Alpha-lipoic acid suppresses 6-hydroxydopamine-induced ROS generation and apoptosis through the stimulation of glutathione synthesis but not by the expression of heme oxygenase-1. Brain Res (2008) 0.85
Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother Pharmacol (2003) 0.84
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol (2006) 0.84
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol (2006) 0.83
Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As2O3. Int J Mol Med (2003) 0.81
Heme oxygenase-1 accelerates protumoral effects of nitric oxide in cancer cells. Virchows Arch (2005) 0.81
Interactions of arsenic with human metallothionein-2. J Biochem (2002) 0.81
Molecular mechanisms and gene regulation of melphalan- and hyperthermia-induced apoptosis in Ewing sarcoma cells. Anticancer Res (2008) 0.78
Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol (2001) 0.77
Co-biomodulation with arsenic trioxide in multiple myeloma. Leuk Res (2001) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006) 5.21
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell (2013) 2.18
Activation of STAT6 by STING is critical for antiviral innate immunity. Cell (2011) 2.08
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood (2011) 2.01
DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog (2012) 1.80
Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol (2013) 1.64
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98. J Immunol (2010) 1.48
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood (2011) 1.47
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33
CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood (2007) 1.31
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med (2011) 1.30
Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol (2004) 1.28
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood (2008) 1.27
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res (2002) 1.15
Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis. J Biol Chem (2005) 1.08
Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood (2002) 1.05
Endoplasmic reticulum stress regulates the innate immunity critical transcription factor IRF3. J Immunol (2012) 1.04
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther (2003) 1.02
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol (2011) 1.01
Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance. Immunity (2013) 1.00
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther (2009) 0.98
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood (2010) 0.98
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood (2011) 0.97
Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release. Mol Cell Biol (2007) 0.97
Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. Oncogene (2005) 0.95
Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Sci Signal (2014) 0.95
Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis. J Immunol (2002) 0.94
Regulation of RelB expression during the initiation of dendritic cell differentiation. Mol Cell Biol (2005) 0.93
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood (2011) 0.93
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood (2010) 0.93
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer (2013) 0.92
Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells. J Biol Chem (2014) 0.91
Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. J Biol Chem (2005) 0.90
A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer (2011) 0.90
Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat (2013) 0.90
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther (2004) 0.88
N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma (2005) 0.88
Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res (2005) 0.87
Speciation, formation, stability and analytical challenges of human arsenic metabolites. J Anal At Spectrom (2009) 0.86
A role for the thermal environment in defining co-stimulation requirements for CD4(+) T cell activation. Cell Cycle (2015) 0.86
Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol (2003) 0.86
Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res (2010) 0.86
EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS One (2010) 0.85
Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother (2005) 0.85
Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J (2002) 0.84
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol (2015) 0.83
Development of target-specific treatments in multiple myeloma. Br J Haematol (2010) 0.83
Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Hum Immunol (2007) 0.83
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma (2011) 0.83
The future of drug development and therapy in myeloma. Semin Oncol (2013) 0.82
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemother Pharmacol (2009) 0.81
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother (2014) 0.81
The Tao of myeloma. Blood (2014) 0.80
Extraction tool and matrix effects on arsenic speciation analysis in cell lines. Anal Chim Acta (2011) 0.79
Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells. Oncoimmunology (2012) 0.79
Protein kinase C blockade inhibits differentiation of myeloid blasts into dendritic cells by calcium ionophore A23187. Int J Hematol (2005) 0.79
Modulation of dendritic cell differentiation and function by YopJ of Yersinia pestis. Eur J Immunol (2007) 0.78
Signal transduction in DC differentiation: winged messengers and Achilles' heel. Adv Exp Med Biol (2007) 0.78
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol (2011) 0.78
The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk Res (2012) 0.78
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. PLoS One (2012) 0.78
Evidence for the requirement of T cell costimulation in the pathogenesis of natural Pneumocystis carinii pulmonary infection. Microb Pathog (2002) 0.77
Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leuk Res (2013) 0.77
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. Oncology (Williston Park) (2011) 0.77
Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymphoma (2003) 0.77
CD28: old dog, new tricks. CD28 in plasma cell/multiple myeloma biology. Adv Exp Med Biol (2009) 0.76
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. Autophagy (2011) 0.76
Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin. Chem Res Toxicol (2014) 0.76
Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway. Int J Cancer (2014) 0.76
Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine. Expert Rev Vaccines (2007) 0.75
6,7-dihydroxy-3,4-dihydroisoquinoline: a novel inhibitor of nuclear factor-kappaB and in vitro invasion in murine mammary cancer cells. Chemotherapy (2009) 0.75